Asthma is a condition in which a patient’s airways narrow and swell and may produce extra mucus. This can make breathing difficult and trigger coughing, a whistling sound (wheezing) when a patient breathes out and shortness of breath. For some people, asthma is a minor nuisance, for others, it can be a major problem that interferes with daily activities and may lead to a life-threatening asthma attack. Asthma cannot be cured, but its symptoms can be controlled. Because asthma often changes over time, it's important that a patient works with doctors to track the signs and symptoms and adjust your treatment as needed. COPD is a chronic inflammatory lung disease, in which airways become blocked, leading to wheezing and shortness of breath.
Market Dynamics
The launch of new products is attributed to the growth of the global asthma and COPD market. For instance, in June 2021, GLENMARK PHARMACEUTICALS LTD, a research-based, global pharmaceutical company, launched Tiogiva, a tiotropium bromide dry powder inhaler (DPI) for the treatment of chronic obstructive pulmonary disease (COPD), in the U.K. Tiogiva’s active ingredient, tiotropium bromide, is a bronchodilator— an agent that relaxes airway muscles so they can widen. Due to its bronchodilator properties, tiotropium can ease several COPD symptoms, including shortness of breath, wheezing, coughing, and chest tightness.
Key features of the study:
- This report provides an in-depth analysis of the global asthma and COPD market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global asthma and COPD market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include AstraZeneca, Novartis AG, GSP plc, Merck & Co., Inc., Verona Pharma plc, Regeneron Pharmaceuticals Inc., and Boehringer Ingelheim International GmbH
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding its future product launches, type up-gradation, market expansion, and marketing tactics
- Global asthma and COPD market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global asthma and COPD market.
Detailed Segmentation:
- Global Asthma And COPD Market, By Drug Type:
- By Drug Type
- Bronchodilators
- Short Acting Bronchodilators
- Long Acting Bronchodilators
- Anti-Inflammatories
- Inhaled Corticosteroids
- Leukotriene Modulators
- Others
- Combined Therapies
- Global Asthma And COPD Market, By Disease type:
- Global Asthma And COPD Market, By Dsitribution Channel:
- Hospital Pharmacies
- Retail Pharemacies
- Online Pharmacies
- Global Asthma And COPD Market, By Region:
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- AstraZeneca
- Novartis AG
- GSP plc,
- Merck & Co., Inc.
- Verona Pharma plc
- Regeneron Pharmaceuticals Inc.
- Boehringer Ingelheim International GmbH.
